

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8367798

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SILVERGATE PHARMACEUTICALS, INC.	04/01/2021
RECEIVING PARTY DATA	
Name:	AZURITY PHARMACEUTICALS, INC.
Street Address:	8 CABOT ROAD, SUITE 2000
City:	WOBURN
State/Country:	MASSACHUSETTS
Postal Code:	01801
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	18203266
CORRESPONDENCE DATA	
Fax Number:	(866)974-7329
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-493-9300
Email:	patentdocket@wsgr.com, tlafortune@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1050
ATTORNEY DOCKET NUMBER:	43060-714.304
NAME OF SUBMITTER:	JOHNSON T. TRUONG
SIGNATURE:	/Johnson T. Truong/
DATE SIGNED:	01/08/2024
Total Attachments: 2	
source=43060-714.304 Assginment Silvergate to Azurity#page1.tif	
source=43060-714.304 Assginment Silvergate to Azurity#page2.tif	

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number 43060-714.101-601

Silvergate Pharmaceuticals, Inc., a corporation formed under the laws of the state of Delaware, having a place of business at 6251 Greenwood Plaza Blvd., Bldg. 6, suite 101, Greenwood Village, Colorado 80111, (the "Assignor"), desires to assign the entire right, title and interest in and to the inventions and Assigned Patents (each, as defined below) to Azurity Pharmaceuticals, Inc., a corporation formed under the laws of the State of Delaware, having a place of business at 8 Cabot Road, Suite 2000, Woburn, MA 01801, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

AMLODIPINE FORMULATIONS

for which the following applications with serial number 62/656,188 filed on April 11, 2018, 16/381,575 filed on April 11, 2019, 17/067,396 filed on October 9, 2020 and PCT/US2019/027044 filed on April 11, 2019 in the United States Patent and Trademark Office

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents in the United States that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) any Patents in the United States to which the Listed Patent(s) claim priority, (d) all Patents applied for in the United States on an invention disclosed within the Patents included in foregoing subclauses (a)-(c), (e) each and every Patent in the United States granting, issuing or reissuing from any of the foregoing under subclauses (a)-(d), and (f) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.

5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.



7. This instrument will be interpreted and construed in accordance with the laws of the state of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number 43060-714.101-601

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:

AGREED TO BY ASSIGNOR: Silvergate Pharmaceuticals, Inc.

Date: 4/1/2021Signature: Name: Hanok M. GeorgeTitle: General Counsel & SecretaryRECEIVED AND AGREED TO BY ASSIGNEE: Azurity
Pharmaceuticals, Inc.Date: 4/1/2021Signature: Name: Hanok M. GeorgeTitle: General Counsel & Secretary